Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease

Clinical and Applied Immunology Reviews

Volumn 2, Issue 1, 2001, Pages 45-63

  Norman, Gary L ^a  

^a INOVA DIAGNOSTICS INC   (United States)

Author keywords

Anti Saccharomyces cerevisiae antibody; Crohn's disease; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; FUNGUS ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY;

BIOASSAY; BIOAVAILABILITY; CHILD CARE; CLINICAL FEATURE; CLINICAL LABORATORY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; ENTERITIS; GASTROINTESTINAL ENDOSCOPY; HISTOLOGY; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; INTESTINE RADIOGRAPHY; MEDICAL ASSESSMENT; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; NORMAL HUMAN; REPRODUCIBILITY; REVIEW; SACCHAROMYCES CEREVISIAE; SENSITIVITY AND SPECIFICITY; SEROLOGY; STANDARDIZATION; ULCERATIVE COLITIS;

EID: 0035526151     PISSN: 15291049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1529-1049(01)00040-X     Document Type: Review

References (98)

1. Loftus Jr. EV, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 1998; 114(6):1161-8.
2. Loftus Jr. EV, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut 2000;46:336-43.
3. Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel sisease. Gastroenterol Clin North Am 1999;28(2):255-81.
4. Niv Y, Abuksis G, Fraser GM. Epidemiology of Crohn's disease in Israel: a survey of Israeli kibbutz settlements. Am J Gastroenterol 1999;94(10):2961-5.
5. Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A. Epidemiology of Crohn's disease in a central Canadian province: a population-based study. Am J Epidemiol 1999;149(10):916-24.
6. Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European collaborative study on inflammatory bowel disease (EC-IBD). Gut 1996;39:690-7.
7. Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman ER. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998;115:822-9.
8. Rutgeerts P, Vermeire S. Clinical value of the detection of antibodies in the serum for diagnosis and treatment of inflammatory bowel disease. Gastroenterology 1998;115:1006-22.
9. Panaccione R, Sanborn WJ. Is antibody testing for inflammatory bowel disease clinically useful? Gastroenterology 1999;116:1001-8.
10. Quinton J-F, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998;42:788-91.
11. Hoffenberg EJ, Fidanza S, Sauaia A. Serologic testing for inflammatory bowel disease. J Pediatrics 1999; 134:447-52.
12. Vermeire S, Peeters M, Rutgeerts P. Diagnostic approach to IBD. Hepatogastoenterology 2000;47:44-8.
13. Coche J-C, Colombel J-F. Heterogeneity of inflammatory bowel disease: clinical subgroups of patients. Res Clin Forums 1998;20(1):135-45.
14. Brant SR, Panhuysen CI, Bailey-Wilson JE, Rohal PM, Lee S, Mann J, et al. Linkage heterogeneity for the IBD1 locus in Crohn's disease pedigrees by disease onset and severity. Gastroenterology 2000;119(6):1483-90.
15. Merck Manual of Diagnosis and Therapy. 1999. Whitehouse Station, NJ. Available from: www.merck.com/ pubs/manual.
16. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Crohn's disease. 1998. NIH Publication No. 98-3410. Available from: www.niddk.nih.gov/health/digest/pubs/crohns/crohns.htm.
17. Peeters M, Geypens B, Claus D, Nevens H, Ghoos Y, Verbeke G, et al. Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology 1997;113(3):802-7.
18. Schmitz H, Barmeyer C, Fromm M, Runkel N, Foss H-D, Bentzel CJ, et al. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology 1999;116:301-9.
19. Peeters M, Cortot A, Vermeire S, Colombel JF. Familial and sporadic inflammatory bowel disease: different entities? Inflamm Bowel Dis 2001;6(4):314-20.
20. Colombel JF, Grandbastein B, Grower-Rousseau C, Plegat S, Evrard JP, Dupas JL, et al. Clinical characteristics of Crohn-s disease in 72 families. Gastroenterology 1996;111:604-7.
21. Peeters M, Nevens H, Baert F, Hiele M, de Meyer AM, Vlietinck R, et al. Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology 1996; 111(3):597-603.
22. Bayless TM, Tokayer AZ, Poloito JM, Quaskey SA, Mellits ED, Harris ML. Crohn's disease: concordance for site and clinical type in affected family members-potential hereditary influences. Gastroenterology 1996; 111(3):573-9.
23. Roth MP, Petersen GM, McElree C, Vadheim CM, Panish JF, Rotter JI. Familial empiric estimates of inflammatory bowel disease in Ashkenazi jews. Gastroenterology 1989;96(4):1016-20.
24. Orholm M, Binder V, Sorensen TIA, Rasmussen LP, Kyvik KO. Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand J Gastroenterol 2000;35:1075-81.
25. Orchard TR, Satsangi J, Van Heel D, Jewell DP. Genetics of inflammatory bowel disease. A reappraisal. Scand J Immunol 2000;51:10-7.
26. Lawrence I, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet 2001;10(5):445-56.
27. Probert CSJ, Jayanthi V, Hughes AO, Thompson JR, Wicks ACB, Mayberry JF. Prevalence and family risk of ulcerative colitis and Crohn's disease: an epidemiological study among Europeans and South Asians in Leicestershire. Gut 1993;34:1547-51.
28. Rachmilewitz D. On smoking, rats, and inflammatory bowel disease. Gastroenterology 2001;117:1008-11.
29. Laharie D, Debeugeny S, Peters M, van Gossum A, Gower-Rousseau C, Belaiche J, et al. Inflammatory bowel disease in spouses and their offspring. Gastroenterology 2001;120:816-9.
30. Probiotics SF, Disease IB. Is there a scientific rationale? Inflam Bowel Dis 2000;6(2):107-15.
31. Strober W, Nakamura K, Kitani A. The SAMP1/Yit mouse: another step closer to modeling human inflammatory bowel disease. J Clin Invest 2001;107(6):667-9.
32. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastoenterology 1998;114:262-7.
33. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10 deficient mice. Infect Immun 1998;66(11):5224-31.
34. ] Rath HC, Wilson KH, Sartor RB. Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteriodies vulgatus or Escherichia coli. Infect Immun 1999;67(6):2969-74.
35. Brandwein SL, McCabe RP, Cong Y, Waites KB, Ridwan BU, Dean PA, et al. Spontaneously colitic C3H/ HeJBir mice demonstrate selective antibody reactivity to antigens of the enteric bacterial flora. Immunol 1997;159:44-52.
36. van Tol EA, Holt L, Li FL, Kong FM, Rippe R, Yamuchi M, et al. Bacterial cell wall polymers promote intestinal fibrosis by direct stimulation of myofibrobalsts. Am J Physiol 1999;277:G245-55.
37. Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunology. 1999;11:648-56.
38. Duchmann R, Kaiser I, Hermann Mayet W, Ewe K, Meyer zum Buschenfelde K-H. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102:448-55.
39. Duchmann R, Meyer zum Buschenfelde K-H. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 1996;26:934-8.
40. Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TE Jr, Bakish E, et al. Normal luminal bacteria, especially bacteroides species mediate chronic colitis, gastritis and arthritis in HLA B27/human beta2 microglobulin transgenic rats. J Clin Invest 1996;98(4):945-53.
41. Schreiber S. Inflammatory bowel disease. Immunologic concepts. Hepatogastroenterology 2000;47:15-28.
42. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205.
43. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics and ecotherapeutics. Gastroenterlogy 2001;120:622-35.
44. Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Shah S, Bousvaros A, et al. Clinical, biological and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001;120:13-20.
45. Nielsen OH, Vainer B, Madsen SM, Seidelin JB, Heegaard HH. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterology 2000;95(2):359-67.
46. Billing P, Tahir S, Calfin B, Gagne G, Cobb L, Targan S, et al. Nuclear localization of the antigen detected by ulcerative colitis-associated perinuclear antineutrophil cytoplasmic antibodies. Am J Path 1995;147(41):979-87.
47. Broberger O, Perlmann P. Autoantibodies in human ulcerative colitis. J Exp Med 1959;110:657-74.
48. Folwaczny C, Noehl N, Tschop K, Endres SP, Heldwein W, Loeschke K, et al. Goblet cell autoantibodies in patients with inflammatory bowel disease and their first-degree relatives. Gastroenterology 1997;113:101-6.
49. Fiocchi C, Roche JK, Michener WM. High prevalence of antibodies to intestinal epithelial antigen in patients with inflammatory bowel disease and their relatives. Ann Int Med 1989;110:786-94.
50. Lee JCW, Cevallos AM, Naeem A, Lennard-Jones JE, Farthing MJG. Detection of anti-colon antibodies in inflammatory bowel disease using human cultured colonic cells. Gut. 1999;44:196-202.
51. Berberian LS, Valles-Ayoub Y, Gordon LK, Targan SR, Braun J. Expression of a novel antibody defined by the VH3-15 gene in inflammatory bowel disease and Campylobacter jejuni enterocolitis. J Immunol 1994; 153(8):3756-63.
52. Geng X, Biancone L, Dai HH, Lin JJ-C, Yoshizaki N, Dasgupta A, et al. Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology 1998; 114:912-22.
53. Fricke H, Birkhofer A, Folwaczny C, Meister W, Scriba PC. Characterization of antigens from the human exocrine pancreatic tissue (Pag) relevant as target antigens for autoantibodies in Crohn's disease. Eur J Clin Invest 1999;29:41-5.
54. Seibold F, Mork H, Tanza S, Muller A, Holzhuter C, Weber P, et al. Pancreatic autoantibodies in Crohn's disease: a family study. Gut 1997;40(4):481-4.
55. Folwaczny C, Noehl N, Endres SP, Loeschke K, Fricke H. Antineutrophil and pancreatic autoantibodies in first degree relatives of patients with inflammatory bowel disease. Scand J Gastroenerol 1998;33:523-8.
56. Hardarson S, Labrecque DR, Mitros FA, Neil GA, Goeken JA. Antineutrophil cytoplasmic antibody in inflammatory bowel and hepatobiliary disease. High prevalence in ulcerative colitis, primary sclerosing cholangitis and autoimmune hepatitis. Am J Clin Pathol 1993;3:277-81.
57. Vidrich A, Lee J, James E, Cobb L, Targan S. Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis. J Clin Immunol 1995;15(6):293-9.
58. Roozendaal C, de Jong MA, van den Berg AP, van Wijk RT, Limburg PC, Kallenberg CG. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases. J Hepatol 2000; 32(5):734-41.
59. Terjung B, Spengler U, Sauerbruch T, Worman HJ. "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000;119:310-22.
60. Duerr RH, Targan SR, Landers CJ, Sutherland LR, Shanahan F. Antineutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses. Gastroenterology 1991;100(6):1590-6.
61. Targan SR, Landers C, Vidrich A, Czaja AJ. High titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology 1995;109(6):2049-50.
62. Davidson IW, Lloyd RS, Whorwell PJ, Wright R. Antibodies to maize in patients with Crohn's disease, ulcerative colitis, and celiac disease. Clin Exp Immunol 1979;35:147-8.
63. Falchuck KR, Isselbacher KJ. Circulating antibodies to bovine albumin in ulcerative colitis and Crohn's disease. Characterization of antibody response. Gastroenterology 1976;70:5-8.
64. Lerner A, Rossi TM, Park B, Albini B, Lebenthal E. Serum antibodies to cows milk proteins in pediatric inflammatory bowel disease. Acta Paediatr Scand 1989;78:384-9.
65. Lindberg E, Magnusson K-E, Tysk C, Jarnerot G. Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease. Gut 1992;33:909-13.
66. Darroch CJ, Barnes RM, Dawson J. Circulating antibodies to Saccharomyces cerevisiae (baker's/brewers' yeast) in gastrointestinal disease. J Clin Pathol 1999;52(1):47-53.
67. Cohavy O, Bruckner D, Gordon LK, Misra R, Wei B, Eggena ME, et al. Colonic bacteria express an ulcerative colitis p-ANCA related protein epitope. Infect Immun 2000;68:1542-8.
68. Blaser MJ, Miller RA, Lacher J, Singleton JW. Patients with active Crohn's disease have elevated serum antibodies to antigens of seven enteric bacterial pathogens. Gastroenterology 1984;87:888-94.
69. Cohavy O, Harth G, Horwitz M, Eggena M, Landers C, Sutton C, et al. Identification of a novel mycobacterial histone H1 homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum immunoglobulin A from patients with Crohn's disease. Infect Immun 1999;67(12):6510-7.
70. El-Zaatari FA, Naser SA, Graham DY. Characterization of a specific Mycobacterium paratuberculosis recombinant expressing 35,000-molecular weight antigen and reactivity with sera from animals with clinical and subclinical Johne's disease. J Clin Microbiol 1997;35(7):1794-9.
71. Naser SA, Hulten K, Shafran I, Graham DY, El-Zaatari FA. Specific seroreactivity of Crohn's disease patients against p35 and p36 antigens of M. avium subsp. paratuberculosis. Vet Microbiol 2000; 77(3-4):497-504.
72. Collins MT, Lisby G, Moser C, Chicks D, Christensen S, Reichelderfer M, et al. Results of multiple diagnostic tests for specific Mycobacterium avium subsp. paratuberculosis in patients with inflammatory bowel disease and in controls. J Clin Microbiol 2000;38(12):4373-81.
73. Main J, McKenzie H, Yeaman GR, Kjerr MA, Robson D, Pennington CR, et al. Antibody to Saccharomyces cerevisiae (baker's yeast) in Crohn's disease. Brit J Med 1988;297:1105-6.
74. McKenzie H, Main J, Pennington CR, Parratt D. Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease. Gut 1990;31:536-8.
75. Sendid B, Colombel JF, Jacquinot PM, Faille C, Fruit J, Cortot A, et al. Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diag Lab Immunol 1996;3(2):219-26.
76. Heelan BT, Allan S, Barnes RM. Identification of a 200 kDa glycoprotein antigen of Saccharomyces cerevisiae. Immunol Lett 1991;28:181-6.
77. Young M, Davies MJ, Bailey D, Gradwell MJ, Smestad-Paulsen B, Wold JK, et al. Characterization of oligosaccharides from an antigenic mannan of Saccharomyces cerevisiae. Glycoconj J 1998;15:815-22.
78. Barnes RM, Allan S, Taylor-Robinson CH, Finn R, Johnson PM. Serum antibodies reactive with S. cerevisiae in inflammatory bowel disease: is IgA antibody a marker for Crohn's disease. Int Arch Allergy Appl Immunol 1990;92(1):9-15.
79. Gaiffer MH, Clark A, Holdsworth CD. Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance. Gut 1992;33:1071-5.
80. Vermeire S, Joossens S, Peeters M, Monsuur F, Marien G, Bossuyt X, et al. Comparative study of ASCA (anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology 2001;120:827-33.
81. Norman GL, Gandhi Z, Crowther T, Binder W, Kratzer V, Reinisch W, et al. IgG and IgA anti-Saccharomyces-cerevisiae antibodies (ASCA) detection by ELISA in Crohn's disease, ulcerative colitis, and healthy patient groups. Gastroenterology 2000;118(4):A694.
82. Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000;47:487-96.
83. Sutton CCL, Yang H, Li Z, Rotter JI, Targan SR, Braun J. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. Gut 2000;46: 58-63.
84. Poulain D, Sendid B, Fajardy I, Danze PM, Colombel JF. Mother to child transmission of anti-S. cerevisiae mannan antibodies (ASCA) in non-IBD families. Gut 2000;47:870-1.
85. Vermeire S, Peeters M, Vlietinck R, Joossens S, Den Hond E, Bulteel V, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis 2001;7(1):8-15.
86. Sendid B, Quinton J-F, Charrier G, Goulet O, Cortot A, Grandbastien B, et al. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol 1998;93(8):1306-10.
87. Norman GL, Gandhi Z, Crowther T, Binder W, Goeken J, Reinisch W, et al. Anti-Saccharomyces cerevisiae (ASCA) IgG and IgA antibodies in inflammatory bowel disease. Association Medical Laboratory Immunologists Annual Meeting. St. Petersburg, FL; August 2000.
88. Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001;96(3):730-4.
89. Braun J, Sutton CL, Yang HY, Rotter J. Reply to letter. Gut 2000;447:870-1.
90. Vasiliauskas EA, Plevy SE, Landers CJ, Binder SW, Ferguson DM, Yang H, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology 1996; 110:1810-9.
91. Joosens S, Cassagnou M, Vermeire S, Peters M, Geboes K, Bossuyt X, et al. Are anti-Saccharomyces cerevisiae antibodies (ASCA) and perinuclear antineutrophil cytoplasmic antibodies (PANCA) useful in indeterminate colitis: A prospective follow-up study. Gastroenterology 2000;118(4):A4899.
92. Vermeire S, Joossens S, Peeters M, Vlietinck R, Rutgeerts P. ASCA and PANCA do not predict response to anti-TNFα(remicade) treatment. Gastroenterology 2000;118(4):A2976.
93. Kam LY, Vasiliauskas EA, Landers CJ, Targan SR. Magnitude of response to remicade correlates with marker antibody expression. Gastroenterology 1999;118(4):G3232.
94. Plevy SE, Vasiliauskas EA, Taylor K, Gaiennie J, Kramer R, Fleshner PR, et al. The Crohn's disease - associated tumor necrosis factor (TNF) microsatellite A2B1C2D4E1 haplotype and anti-Saccharomyces cerevisiae antibody (ASCA) define medically resistant forms of ulcerative colitis. Gastroenterology 1997;112: A1062.
95. Reddy KR, Colombel J-F, Poulain D, Krawitt KL. Anti-S. cerevisiae antibodies in autoimmune liver disease. Am J Gastroenterology 2001;96(1):252-3.
96. Dubinsky MC, Ofman JJ, Urman M, Targan SR, Seidmen EG. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol 2001;96(3):758-65.
97. Check W. Shades of grey in gastrointestinal testing. CAP Today 2000;14(8):1.
98. Abeu MT, Vasiliauskas EA, Kam LY, Dubinsky MC. Use of serologic tests in Crohn's disease. Clin Perspect Gastroenterol 2001;3:155-64.